ArticleNPJ Parkinson's disease2026
Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson's disease.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive decline is a major non-motor complication in early Parkinson's disease (PD), but predicting its progression remains challenging. Using data from 193 participants in the Early Parkinson's Disease Longitudinal Singapore (PALS) cohort, we evaluated whether repeated blood biomarker measurements (baseline, year 3, year 5)-neurofilament light chain (NfL) and total tau (t-tau)-could improve prediction of cognitive decline, defined as a one-point annual or sustained two-year drop in Montreal Cognitive Assessment scores. We applied three variable selection methods and five machine learning models across seven feature sets. Overall, 23% of participants experienced cognitive decline over five years. The XGBoost model trained on Random Forest-selected variables achieved the highest performance (AUC = 0.806), a substantial improvement over the baseline-only model (AUC = 0.560). Key predictors included diastolic blood pressure and summaries of t-tau and NfL. Time-varying biomarkers improved predictions over baseline data alone, supporting their integration with machine learning for early cognitive risk assessment in PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.